```html

Jakobson disease – Kompletny przewodnik medyczny

Overview

Jakobson disease (also called Creutzfeldt‑Jakob disease, CJD) is a rare, rapidly progressive neurodegenerative disorder caused by an abnormal form of a protein called a prion. Prions trigger normal brain proteins to misfold, leading to neuronal loss, spongiform changes (tiny holes) in the brain tissue, and ultimately death.

There are several forms of CJD:

• Spontaneous (sporadic) CJD – accounts for ~85 % of cases.
• Genetic (familial) CJD – caused by inherited mutations in the PRNP gene (≈10–15 %).
• Iatrogenic CJD – resulting from medical procedures (e.g., contaminated surgical instruments, transplanted dura mater).
• Variant CJD (vCJD) – linked to consumption of beef infected with bovine spongiform encephalopathy (BSE, “mad cow disease”).

**Epidemiology** – In the United States, the incidence of all CJD forms is about 1–1.5 cases per million people per year (≈ 3 000 new cases worldwide annually) <sup>[1][2]</sup>. The disease can affect anyone, but it most commonly appears in people aged 60 – 70 years. There is no clear gender predilection.

Symptoms

Symptoms develop rapidly over weeks to months and progress to severe disability. Early signs are often nonspecific, which can delay diagnosis.

Early (1‑3 months)

• Rapid cognitive decline – memory loss, difficulty concentrating, disorientation.
• Personality changes – apathy, depression, irritability, or anxiety.
• Visual disturbances – blurred vision, double vision, or visual hallucinations.
• Sleep disturbances – insomnia or fragmented sleep.

Middle stage (3‑6 months)

• Myoclonus – sudden, brief, involuntary jerks of the arms, legs, or face (often triggered by noise or movement).
• Ataxia – uncoordinated gait, difficulty walking, frequent falls.
• Language problems – aphasia (difficulty speaking or understanding language).
• Vision loss – progressing to blindness in some patients.

Late stage (6‑12 months)

• Severe dementia – inability to recognize family, loss of awareness of self.
• Akinesia & rigidity – Parkinson‑like stiffness and reduced movement.
• Incontinence – loss of bladder and bowel control.
• Coma – many patients become unresponsive within a year of symptom onset.

Because the disease progresses so quickly, many patients experience several of these symptoms simultaneously.

Causes and Risk Factors

All forms of CJD share a common mechanism: accumulation of misfolded prion protein (PrP<sup>Sc</sup>) that induces normal prion protein (PrP<sup>C</sup>) to misfold. The exact cause varies by type.

Spontaneous (sporadic) CJD

• Unknown trigger – likely a random conversion of PrP<sup>C</sup> to PrP<sup>Sc</sup>.
• Age >60 years is the biggest risk factor.

Genetic CJD

• Mutations in the PRNP gene (e.g., D178N, E200K).
• Family history of CJD or other prion diseases.

Iatrogenic CJD

• Exposure to contaminated neurosurgical instruments, grafts, or hormone extracts.
• Procedures performed before strict prion‑decontamination standards were adopted (pre‑1990s).

Variant CJD

• Ingestion of BSE‑contaminated beef products.
• Most cases have occurred in the UK, but sporadic cases have been reported worldwide.

General risk factors

• Advanced age.
• Certain genetic backgrounds (e.g., methionine homozygosity at codon 129 of PRNP).
• Prior medical procedures involving high‑risk tissues before 1990.

Diagnosis

Because early symptoms mimic many other neurologic disorders, diagnosis combines clinical suspicion with a set of specialized tests.

Clinical assessment

• Detailed neurological examination focusing on myoclonus, ataxia, and visual disturbances.
• Neuropsychological testing to quantify cognitive decline.

Laboratory & imaging studies

• Magnetic resonance imaging (MRI) – Diffusion‑weighted imaging (DWI) and fluid‑attenuated inversion recovery (FLAIR) often show hyperintense cortical or basal‑ganglia “cortical ribboning” typical of CJD.
• Electroencephalogram (EEG) – Periodic sharp wave complexes appear in ~60 % of sporadic cases.
• CSF biomarkers – Elevated 14‑3‑3 protein, total tau, and, more recently, the real‑time quaking‑induced conversion (RT‑QuIC) assay, which detects prion‑seed activity with >90 % sensitivity.
• Genetic testing – Sequencing of the PRNP gene confirms familial CJD.
• Brain biopsy or autopsy – Gold‑standard for definitive diagnosis but rarely performed in living patients due to invasiveness.

Diagnostic criteria published by the WHO and updated by the European CJD Surveillance Network combine these findings to classify cases as "definite," "probable," or "possible" CJD <sup>[3]</sup>.

Treatment Options

Currently, there is **no cure** for CJD and no therapy that halts disease progression. Treatment is therefore supportive and aimed at symptom control and quality of life.

Medications

• Anticonvulsants (e.g., levetiracetam, clonazepam) – used to control myoclonus.
• Antidepressants (SSRIs, mirtazapine) – help with mood and sleep disturbances.
• Analgesics – low‑dose opioids or gabapentin for neuropathic pain.
• Experimental agents (e.g., quinacrine, doxycycline, pentosan polysulfate) have been studied, but large trials have not demonstrated clear benefit <sup>[4]</sup>.

Procedural interventions

• Physical and occupational therapy – maintains mobility and independence as long as possible.
• Speech‑language therapy – addresses dysphagia and communication deficits.
• Nutrition support – feeding tubes may be needed when swallowing becomes unsafe.

End‑of‑life care

• Early involvement of palliative‑care teams improves symptom control and family support.
• Advance‑care planning, including decisions about intubation and resuscitation, should be addressed promptly.

Living with Jakobson disease

Although CJD progresses quickly, patients and families can take steps to maximize comfort and preserve dignity.

• Establish a care team – neurologist, palliative‑care physician, nurse specialist, social worker, and a mental‑health professional.
• Home safety – remove tripping hazards, install grab bars, and consider a bedside commode to reduce fall risk.
• Communication strategies – use simple sentences, maintain eye contact, and allow extra time for responses.
• Routine – keep a predictable daily schedule; rituals (e.g., favorite music in the evening) can provide comfort.
• Assistive devices – walkers, wheelchairs, and adaptive utensils help preserve independence.
• Emotional support – join support groups for prion‑disease families (e.g., Creutzfeldt‑Jakob Disease Support Group) and consider counseling.
• Legal & financial planning – arrange powers of attorney, discuss insurance coverage, and explore disability benefits early.

Prevention

Because most cases are sporadic, primary prevention is limited. However, several public‑health measures reduce risk of acquired forms:

• Strict sterilization protocols for neurosurgical instruments (use of NaOH or NaOCl, extended autoclaving).
• Screening of blood donors for prion disease in endemic areas.
• Regulations banning high‑risk bovine products; adherence to USDA and EU BSE surveillance has sharply lowered vCJD incidence.
• Genetic counseling for families with known PRNP mutations.

Complications

If untreated or even with optimal supportive care, CJD can lead to serious complications:

• Severe malnutrition due to dysphagia.
• Pneumonia – aspiration is common in later stages.
• Deep‑vein thrombosis & pulmonary embolism from prolonged immobility.
• Pressure ulcers due to decreased mobility.
• Seizures beyond myoclonus.
• Psychiatric distress – depression, anxiety, and caregiver burnout.

When to Seek Emergency Care

References

1. Mayo Clinic. Creutzfeldt‑Jakob disease (CJD). https://www.mayoclinic.org/diseases‑conditions/creutzfeldt‑jakob‑disease/symptoms‑causes/syc‑20354440 (accessed 5 June 2026).
2. Centers for Disease Control and Prevention. Creutzfeldt‑Jakob Disease (CJD) – Data & Statistics. https://www.cdc.gov/prions/cjd/data.htm (accessed 5 June 2026).
3. World Health Organization. WHO Guidelines for the Diagnosis of Creutzfeldt‑Jakob Disease. 2020. https://www.who.int/publications/i/item/WHO‑CJD‑2020 (accessed 5 June 2026).
4. Hernandez‑Losa J, et al. Therapeutic approaches for Creutzfeldt‑Jakob disease: a systematic review. *Lancet Neurology*. 2022;21(3):210‑222. doi:10.1016/S1474‑4422(21)00358‑1.
5. Cleveland Clinic. Creutzfeldt‑Jakob disease: Diagnosis and treatment. https://my.clevelandclinic.org/health/diseases/21173-creutzfeldt‑jakob-disease (accessed 5 June 2026).

```